Jeito is a next-generation fund with a patient benefit driven approach, that focuses both on financing ground-breaking medical innovation and promoting positive societal impact. We empower and support entrepreneurs through our expert, integrated, multi-talented team.
Jeito Capital is based in Paris with a presence in Europe and the United States.
Follow us to get our latest news & job offers.
Jeito Capital is based in Paris with a presence in Europe and the United States.
Follow us to get our latest news & job offers.
Location: France, Ile-de-France, Paris
Employees: 11-50
Founded date: 2017
Investment Type: Venture Capital
Investment Stage: Series A; Series B; Series C
Portfolio 15
| Date | Name | Website | Total Raised | Location |
| 09.02.2024 | Advesya | advesya.com | - | - |
| 01.11.2023 | Corteria P... | corteriapharma.com | $69.6M | France, Il... |
| 09.05.2023 | Noema Phar... | noemapharma.com | $173.56M | Switzerlan... |
| 13.04.2023 | Alentis Th... | alentis.ch | $185.66M | Switzerlan... |
| 14.09.2022 | SparingVis... | sparingvision.com | $202.94M | France, Il... |
| 16.04.2022 | HI-Bio | hibio.com | $215M | United Sta... |
| 16.04.2022 | Catalym | catalym.com | $261.12M | Germany, B... |
| 13.04.2022 | CDR-Life I... | cdr-life.com | $76M | Switzerlan... |
| 17.03.2022 | Precirix | precirix.com | $88.41M | - |
| 27.02.2022 | NMD Pharma | nmdpharma.com | $121.42M | Denmark, A... |
Show more
Persons 3
| Date | First Name | Last Name | Title | Location | |||
| - | Alain | - | Chief Fina... | - | - | - | |
| - | Manon | - | Project Ma... | - | - | - | |
| - | Evaldo | - | Head of Co... | - | - | - |
Mentions in press and media 21
| Date | Title | Description |
| 29.05.2024 | Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio for a potential value of $3 billion | - |
| 07.09.2023 | Corteria Pharmaceuticals Announces a €65M Financing to Advance Transformational Medicines in Cardiovascular Diseases | Corteria Pharmaceuticals (“Corteria”), a biopharmaceutical company specialized in the development of transformative therapies for unaddressed heart failure subpopulations, today announced an oversubscribed €65M ($71M) Series A co-led by US ... |
| 13.04.2023 | Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for claudin-1 in cancer & fibrosis | - |
| 13.04.2023 | Alentis Therapeutics closes USD 105 million Series C round | |
| 07.03.2023 | Noema Pharma raises CHF103 million | |
| 13.04.2022 | CDR-Life Closes $76 million Series A Funding | |
| 17.03.2022 | Precirix raises EUR 80m in Series B to advance its pipeline of precision radiopharmaceuticals | Brussels, Belgium, 16 March 2022 – Precirix NV, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology, today announces the closing of a EUR 80m Series B financing round led by new investors INKEF Capit... |
| 29.11.2021 | Syncona : Quell Therapeutics Raises $156 million in Oversubscribed Series B Financing to Advance its Pioneering Multi-Modular Engineered T Regulatory (Treg) Cell Therapy Pipeline and Platform | - Series B co-led by Jeito Capital, Ridgeback Capital Investments, SV Health Investors and Fidelity Management & Research Company LLC, alongside founding investor Syncona and includes a broad syndicate of international life science focu... |
| 29.11.2021 | Jeito Capital Co-Leads $156 Million Oversubscribed Series B Financing In Quell Therapeutics | Jeito Capital co-leads $156 million oversubscribed Series B financing in Quell Therapeutics Quell Therapeutics is the world leader in developing engineered T-regulatory (Tregs) cell therapies for serious medical conditions driven by the imm... |
| 29.11.2021 | Quell Therapeutics Raises $156 million in Oversubscribed Series B Financing to Advance its Pioneering Multi-Modular Engineered T Regulatory (Treg) Cell Therapy Pipeline and Platform | - Series B co-led by Jeito Capital, Ridgeback Capital Investments, SV Health Investors and Fidelity Management & Research Company LLC, alongside founding investor Syncona and includes a broad syndicate of international life science focu... |
Show more